FDA Approves DefenCath (taurolidine and heparin) to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients

Berkeley Heights, NJ– November 15, 2023–  CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news